•$Day One Biopharmaceuticals (DAWN.US)$+67.7% (Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma)
•$Gracell Biotechnologies (GRCL.US)$+12.1% (Presents Updated Clinical Data for BCMA/CD19 Dual-targeting FasTCAR GC012F in RRMM at EHA2022 Congress, Highlighting 100% MRD Negativity Rate in All Treated Patients)
•$OptiNose (OPTN.US)$+2.7% (top-line results of ReOpen2, its second phase 3 clinical trial of XHANCE for treatment of chronicsinusitis)
•$Ionis Pharmaceuticals (IONS.US)$+2.6% (treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA)
•$Apellis Pharmaceuticals (APLS.US)$+2.3% (receives FDA orphan designation for Pegcetacoplan, treatment of immune complex-membranoproliferative glomerulonephritis)
•$Astra Space (ASTR.US)$-21.8% (tweets "We had a nominal first stage flight. The upper stage shut dow nearly and we did not deliver the payloads to orbit. We have shared our regrets with NASA and the payload team. More information will be provided after we complete a full data review")
•$Cogent Biosciences (COGT.US)$-12.7% (commenced an underwritten public offering of $125 million of shares of its common stock)
•$BeiGene (BGNE.US)$-2.4% (has extended the Prescription Drug User Fee Actgoaldate by three months to January 20 2023 for the supplementary new drug application for BRUKINSA as a treatment for adult patients with chroniclymphocytic leukemia orsmall lymphocytic lymphoma)
Giovanni Ayala :
SpyderCall : don't forget to mention the crash of the cryptocurrency Celsius which caused a meltdown in just about every other crypto
71018838 : No mention of RDBX up 30%???
Stuka II 71018838 : That’s way too thigh to chase, buddy
whqqq : It's all very detailed information